Sorafenib is primarily used as a targeted therapy in the treatment of advanced renal cell carcinoma (kidney cancer), hepatocellular carcinoma (liver cancer), and differentiated thyroid carcinoma. It works by inhibiting multiple kinases involved in tumor growth and angiogenesis, thereby slowing the progression of these cancers. In liver cancer, it is often prescribed when surgical options are not viable. For kidney cancer, it is used when the disease has spread or become resistant to other treatments. In thyroid cancer, it is employed for cases that are no longer responsive to radioactive iodine therapy. The drug is administered orally, allowing for convenient outpatient treatment, and is typically taken twice daily. Regular monitoring is required to manage potential side effects, such as hypertension, skin reactions, and gastrointestinal issues.